For the quarter ending 2025-09-30, BBNX made $27,253,000 in revenue. -$14,004,000 in net income. Net profit margin of -51.39%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net sales | 27,253,000 | 23,238,000 | 17,639,000 | 16,281,000 |
| Cost of sales | 12,134,000 | 10,735,000 | 8,668,000 | 7,309,000 |
| Gross profit | 15,119,000 | 12,503,000 | 8,971,000 | 8,972,000 |
| Research and development | 8,195,000 | 8,873,000 | 7,590,000 | 6,546,000 |
| Sales and marketing | 16,045,000 | 15,623,000 | 13,402,000 | 9,271,500 |
| General and administrative | 7,922,000 | 7,879,000 | 6,621,000 | 4,467,250 |
| Total operating expenses | 32,162,000 | 32,375,000 | 27,613,000 | 20,284,750 |
| Loss from operations | -17,043,000 | -19,872,000 | -18,642,000 | -11,312,750 |
| Interest income | 2,833,000 | 3,005,000 | 2,436,000 | 977,250 |
| Other income (expense), net | 1,000 | -2,000 | - | -500 |
| Change in fair value of warrant liabilities | 0 | 0 | 12,450,000 | 3,353,000 |
| Total other income (expense), net | 2,834,000 | 3,003,000 | -10,014,000 | -2,376,250 |
| Net loss | -14,209,000 | -16,869,000 | -28,656,000 | -13,689,000 |
| Unrealized gain (loss) on short-term investments | 205,000 | -91,000 | 175,000 | -18,000 |
| Comprehensive loss | -14,004,000 | -16,960,000 | -28,481,000 | -13,707,000 |
| Earnings per share, basic | -0.33 | -0.39 | -0.93 | -2.15 |
| Earnings per share, diluted | -0.33 | -0.39 | -0.93 | -2.15 |
| Weighted average number of shares outstanding, basic | 43,634,006 | 43,390,652 | 30,714,769 | 1,591,266 |
| Weighted average number of shares outstanding, diluted | 43,634,006 | 43,390,652 | 30,714,769 | 1,591,266 |
Beta Bionics, Inc. (BBNX)
Beta Bionics, Inc. (BBNX)